Discover
SGHT
Sight Sciences, Inc.
5.44
2 x 3.99
2 x 6.78
bid
ask
+
0.02
0.37%
2 @ 04:00 PM
5.44 +0.00 (0.00%)
| Ytd | -31.40% | |
| 1y | 33.66% |
5.25
day range
5.60
3.11
52 week range
9.24
| Open | 5.39 | Prev Close | 5.42 | Low | 5.25 | High | 5.60 | Mkt Cap | 295.99M |
| Vol | 206.47K | Avg Vol | 241.58K | EPS | -0.70 | P/E | N/A | Forward P/E | -4.33 |
| Beta | 2.73 | Short Ratio | 3.66 | Inst. Own | 51.10% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 4.85 | 200-d Avg | 5.36 | 1yr Est | 5.02 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.23 | -0.22 | 0.01 | 4.35% |
| 2024-08-01 | 2024-06 | -0.31 | -0.25 | 0.06 | 19.35% |
| 2024-08-01 | 2024-06 | -0.31 | N/A | N/A | N/A |
| 2024-05-02 | 2024-03 | -0.29 | -0.33 | -0.04 | -13.79% |
| 2024-05-02 | 2024-03 | -0.29 | N/A | N/A | N/A |
| 2024-03-07 | 2023-12 | -0.35 | -0.22 | 0.13 | 37.14% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-11 | Citigroup | Upgrade | Neutral | Neutral |
| 2024-12-06 | UBS | Upgrade | Buy | |
| 2024-11-11 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
| 2024-11-08 | Piper Sandler | Upgrade | Neutral | Neutral |
| 2024-11-08 | Needham | Upgrade | Hold | |
| 2024-08-21 | Lake Street | Upgrade | Buy |
Profile
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-01 | BADAWI DAVID | Chief Technology Officer | 1.76M | Sale |
| 2024-10-01 | BADAWI PAUL | Chief Executive Officer | 5.73M | Sale |
| 2024-09-30 | BAUERLEIN ALISON | Chief Financial Officer | 392.56K | Sale |
| 2024-11-20 | ENCRANTZ STAFFAN | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-09-30 | HAYDEN JEREMY BRAGG | Officer | 158.69K | Sale |
| 2024-10-20 | LINK MATTHEW W | Officer | 663.55K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | UBS Group AG | 2.53M | 8.89M | 4.99% |
| 2024-09-29 | Blackrock Inc. | 2.24M | 7.85M | 4.41% |
| 2024-09-29 | Bank of America Corporation | 2.10M | 7.39M | 4.15% |
| 2024-09-29 | Vanguard Group Inc | 1.69M | 5.93M | 3.33% |
| 2024-09-29 | Jackson Square Partners, Llc | 918.06K | 3.22M | 1.81% |
| 2024-09-29 | Long Focus Capital Management, LLC | 865.10K | 3.04M | 1.70% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 933.75K | 3.28M | 1.84% |
| 2024-10-30 | iShares Russell 2000 ETF | 861.86K | 3.03M | 1.70% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 459.34K | 1.61M | 0.91% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 360.81K | 1.27M | 0.71% |
| 2024-10-30 | iShares Russell 2000 Growth ETF | 304.77K | 1.07M | 0.60% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 179.04K | 628.42K | 0.35% |